Drug Profile

CB 001- Zhimeng Biopharma

Alternative Names: CB HBV 001; CB-001 - Zhimeng Biopharma; CB-01

Latest Information Update: 29 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zhimeng Biopharma
Class Antivirals; Oxazolidinones; Pyrazoles; Small molecules; Stem cell therapies
Mechanism of Action Capsid protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hepatitis B

Most Recent Events

29 Aug 2023 Phase-II clinical trials in Hepatitis B in China (Parenteral) (Zhimeng Biopharma pipeline, August 2023)
12 Jan 2022 Phase-I clinical trials in Hepatitis B in China (Parenteral) (Zhimeng Biopharma pipeline, January 2022)
21 Feb 2019 Updated pharmacodynamics data from preclinical trials in Hepatitis B released by Zhimeng Biopharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com